Innate Pharma S.A. (IPH) Shifts PACIFIC-9 Readout to H1 2027

Innate Pharma (IPH) announced that AstraZeneca revised the expected high-level data release from the PACIFIC-9 Phase 3 trial to H1 2027, delayed from H2 2026, due to the study's event-driven nature. Enrollment is complete, according to the company.

Original reporting
Published Oct 27, 2026, 6:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 6:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Innate Pharma S.A. (IPH) Shifts PACIFIC-9 Readout to H1 2027 — source image
Decision brief

The 30-second read

$IPHABearishLow
01

Why it matters

The readout postponement pushes a major catalyst out by roughly 1.5 years, likely dampening near-term valuation.

02

Market read

The news primarily affects IPHA shareholders; broader market impact is minimal.

03

What to watch

AstraZeneca's continued partnership and potential future collaborations may mitigate the short-term downside.

Relevance 8/10Novelty 8/10Timing: today

Background

Innate Pharma (NASDAQ: IPHA) partners with AstraZeneca on the PACIFIC-9 immunotherapy program targeting lung cancer.

Company-level read

Ticker impact

$IPHABearishHigh confidence
Context

Innate Pharma announced the PACIFIC-9 Phase 3 readout is pushed to H1 2027, delaying a key catalyst.

Expected impact

likely pressure as the market prices in the later readout date

Evidence & confidence

Investors typically discount stocks when a major clinical milestone is postponed, especially for a partnered asset.

Market effects

Biotech sector may see modest repricing of other late-stage trial timelines.

European biotech markets could experience slight dip due to the delay.

Limited; impact confined to Innate Pharma and peers with similar trial timelines.

Counterpoint

The delay could be viewed positively if it reflects thorough data collection, potentially leading to a stronger readout.

Key entities

  • Innate Pharma S.A.

    Biotech firm developing immunotherapies.

  • AstraZeneca

    Partner and co-developer of PACIFIC-9.

Related articles

$IPHAHighAI 8/10

Why is Innate Pharma stock sliding today?

Innate Pharma (IPH) shares fell 21.1% to $1.05 after presenting Phase 1 clinical data for IPH4502. The drug showed a 33% response rate in non-urothelial tumors but modest results in urothelial cancer, its primary target. BTIG had a $9.00 price target, but the data underwhelmed, leading to a 52-week low of $1.01. The broader market decline also contributed to the sell-off.

$IPHAMedAI 8/10

Innate Pharma SA: Innate Pharma Presents Initial Phase 1 Clinical Data for IPH4502 at ENA 2026

Innate Pharma presented initial Phase 1 data for IPH4502, an investigational Nectin-4-targeting antibody-drug conjugate, at the ENA 2026 symposium. The study showed encouraging tolerability and antitumor activity across multiple tumor types, including urothelial cancer. The maximum tolerated dose was 3.6 mg/kg, with stomatitis as the only dose-limiting toxicity.

$IPHAMed

Innate Pharma stock maintained at Buy by BTIG on pipeline progress

BTIG maintained a Buy rating and $9.00 price target on Innate Pharma (NASDAQ:IPHA) after its Q3 2026 results. The stock trades at $2.87, with a Fair Value of $4.13. Upcoming catalysts include IPH4502 phase 1 data and PACIFIC-9 readout. The company has €96.8 million in cash, covering operations through Q1 2028. Recent developments include a $75 million upfront payment from a partnership with Swedish Orphan Biovitrum.

$AZNMed

AstraZeneca delays PACIFIC-9 lung cancer trial data to H1 2027

Innate Pharma (IPH, IPHA) announced AstraZeneca (AZN) delayed the PACIFIC-9 trial data to H1 2027 from H2 2026, citing the study's event-driven nature. The trial tests durvalumab with monalizumab or oleclumab in Stage III lung cancer. Monalizumab is co-developed by Innate and AZN. Innate Pharma is a clinical-stage biotech listed in Paris and on Nasdaq.